Enterococcus faecalis lysant

Abstract

The present invention addresses the problem of providing a novel bacteriolytic agent capable of lysing a bacterium belonging to the genus Enterococcus.　Provided is a bacteriolytic agent against a bacterium belonging to the genus Enterococcus that comprises a lytic enzyme containing any of: (a) the amino acid sequence represented by SEQ ID NO. 1; (b) an amino acid sequence resulting from addition, deletion and / or substitution of one or more amino acids in the amino acid sequence represented by SEQ ID NO. 1; or (c) an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO. 1, or an active fragment thereof.

Claims

[Claim 1] A pharmaceutical composition for the treatment or prevention of intestinal dysbiosis, Containing a lytic enzyme or its active fragment, The aforementioned lytic enzyme, (a) The amino acid sequence shown in Sequence ID No. 1, or (b) an amino acid sequence in which the amino acid sequence shown in Sequence ID No. 1 includes an enzyme activity domain consisting of positions 3 to 202 and a cell wall binding domain consisting of positions 223 to 329, and in which one or two amino acids are added, deleted, and / or substituted in the amino acid sequence shown in Sequence ID No.

1. Includes, The pharmaceutical composition comprising the enzyme-active domain and the cell wall-binding domain as the active fragment. [Claim 2] The pharmaceutical composition according to claim 1, wherein the lytic enzyme comprises the amino acid sequence shown in Sequence ID No.

1. [Claim 3] A pharmaceutical composition for the treatment or prevention of intestinal dysbiosis, It contains a polynucleotide encoding a lytic enzyme or an active fragment thereof, The aforementioned lytic enzyme, (a) The amino acid sequence shown in Sequence ID No. 1, or (b) an amino acid sequence in which the amino acid sequence shown in Sequence ID No. 1 includes an enzyme activity domain consisting of positions 3 to 202 and a cell wall binding domain consisting of positions 223 to 329, and in which one or two amino acids are added, deleted, and / or substituted in the amino acid sequence shown in Sequence ID No.

1. Includes, The pharmaceutical composition comprising the enzyme-active domain and the cell wall-binding domain as the active fragment. [Claim 4] The pharmaceutical composition according to claim 3, wherein the polynucleotide comprises the base sequence shown in Sequence ID No.

2. [Claim 5] The pharmaceutical composition according to claim 4, comprising an expression vector containing the polynucleotide. [Claim 6] The pharmaceutical composition according to any one of claims 1 to 5, further comprising a pharmaceutically acceptable carrier. [Claim 7] The pharmaceutical composition according to claim 6, wherein the intestinal dysbiosis is graft-versus-host disease or alcoholic liver disease. [Claim 8] The pharmaceutical composition according to claim 6, wherein the intestinal dysbiosis is graft-versus-host disease. [Claim 9] A pharmaceutical composition according to any one of claims 1 to 5, formulated as an enteric-coated preparation. [Claim 10] The pharmaceutical composition according to claim 6, wherein the carrier is one or more selected from the group consisting of excipients, binders, disintegrants, fillers, emulsifiers, flow additive regulators, and lubricants. [Claim 11] A pharmaceutical composition according to any one of claims 1 to 5, which is administered orally, rectally, intraperitoneally, or intravenously.

Images